Overview

• Researchers prospectively enrolled 2,978 women with dense breasts across five U.S. sites for two annual screening rounds from 2017 to 2022, with one-year follow-up completed in September 2024.
• MBI detected 30 cancers in 29 participants that were not seen on digital breast tomosynthesis, most of them invasive with a median invasive lesion size of 0.9 cm.
• Incremental detection from adding MBI was 6.7 additional cancers per 1,000 screens in Year 1 and 3.5 per 1,000 in Year 2.
• The combined strategy identified more node-positive cancers than DBT alone in both rounds, including 7 of 7 cases in Year 1 versus 4 of 7 by DBT.
• Authors report MBI was well tolerated and relatively inexpensive, and they note the mix of academic and community sites with 12% minority enrollment supports generalizability.